Long-term effects of polymer-based, slow-release, sirolimus-eluting stents in a porcine coronary model

Cardiovascular Research

Volumn 63, Issue 4, 2004, Pages 617-624

  Carter, Andrew J ^a   Aggarwal, Meenakshi ^b   Kopia, Gregory A ^c   Tio, Fermin ^d   Tsao, Philip S ^b   Kolata, Ron ^e   Yeung, Alan C ^b   Llanos, Gerald ^c   Dooley, John ^c   Falotico, Robert ^c  

^a PROVIDENCE ST VINCENT MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^c Department of Medical Affairs and Health Ecomomics Worldwide   (United States)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^e ETHICON INC   (United States)

Author keywords

Cell cycle; Restenosis; Smooth muscle; Stents

Indexed keywords

CD45 ANTIGEN; CYCLIN DEPENDENT KINASE; CYCLINE; CYPHER; DRUG CARRIER; INTERLEUKIN 2; INTERLEUKIN 6; LYMPHOTOXIN; MONOCYTE CHEMOTACTIC PROTEIN 1; POLYMER; PROTEIN P27; RAPAMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTICLE; BIOLOGICAL MODEL; BLOOD VESSEL REACTIVITY; BLOOD VESSEL WALL; CELL PROLIFERATION; CONTROLLED STUDY; CORONARY ARTERY; DRUG EFFECT; DRUG ELUTING STENT; EVALUATION; HISTOLOGY; IMPLANTATION; LONG TERM CARE; MODULATION; NONHUMAN; POSTOPERATIVE COMPLICATION; POSTOPERATIVE THROMBOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SWINE; THROMBUS; WESTERN BLOTTING;

ANIMALS; BIOLOGICAL MARKERS; CELL CYCLE; CELL CYCLE PROTEINS; CORONARY RESTENOSIS; CORONARY STENOSIS; CORONARY VESSELS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DELAYED-ACTION PREPARATIONS; IMMUNOSUPPRESSIVE AGENTS; MODELS, ANIMAL; POLYMERS; PROLIFERATING CELL NUCLEAR ANTIGEN; SIROLIMUS; STENTS; SWINE; SWINE, MINIATURE; TIME FACTORS; TREATMENT FAILURE; TUMOR SUPPRESSOR PROTEINS; TUNICA INTIMA;

EID: 4043137360     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cardiores.2004.04.029     Document Type: Article

References (15)

1. Suzuki T., Wilenski R., Bailey L.R., et al. Stent-based sirolimus therapy reduces neointimal formation and in-stent restenosis in a porcine coronary model. Circulation. 104:2001;1188-1193
2. Klugherz B.D., Llanos G., Lieuallen W., et al. Stent-based delivery of sirolimus for the prevention of restenosis. Coron. Artery Dis. 13:2002;183-188
3. Schwartz R.S., Huber K.C., Murphy J.G., et al. Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. J. Am. Coll. Cardiol. 19:1991;267-274
4. Kornowski R., Hong M.K., Tio F.O., Bramwell O., Wu H., Leon M.B. In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J. Am. Coll. Cardiol. 31:1998;224-230
5. Welt F.G.P., Rogers C. Inflammation and restenosis in the Stent Era. Arterioscler Thromb. Vasc. Biol. 22:2002;1769-1776
6. Gallo R., Padurean A., Jayaraman T., et al. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation. 99:1999;2164-2170
7. Braun-Dullaeus R.C., Mann M.J., Seay U., et al. Cell cycle protein expression in vascular smooth muscle cells in vitro and in vivo is regulated through phosphatidylinositol 3-kinase and mammalian target of rapamycin. Arterioscler Thromb. Vasc. Biol. 21:2001;1152-1158
8. Sousa J.E., Costa M.A., Abizaid A.C., et al. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries. Circulation. 103:2001;192-195
9. Sousa J.E., Abizaid A., Abizaid A., et al. Late (three-year) follow-up from the first-in-man (FIM) experience after implantation of sirolimus-eluting stents. Circulation. 106(Suppl. II):2002;II-394. [Abstract]
10. Morice M.C., Serruys P.W., Sousa J.E., et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N. Engl. J. Med. 346:2002;1773-1780
11. Serruys P.W., Degertekin M., Tanabe K., et al. Intravascular ultrasound findings in the multicenter, randomized, double-blind RAVEL (RAndomized study with the sirolimus-eluting VElocity balloon-expandable stent in the treatment of patients with de novo native coronary artery Lesions) trial. Circulation. 106:2002;798-803
12. Moses J.W., Leon M.B., Popma J.J., et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N. Engl. J. Med. 349:2003;1315-1323
13. Morice M.C., Serruys P., Constantini C., et al. Three-year follow-up of the RAVEL study: A randomized study with the sirolimus-eluting velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery lesions. J. Am. Coll. Cardiol. 43:2004;87A. [Abstract]
14. Wright D.C., Deol H.S., Tuch B.E. A comparison of the sensitivity of pig and human peripheral blood mononuclear cells to the antiproliferative effects of traditional and newer immunosuppressive agents. Transpl. Immunol. 7:1999;141-147
15. Zohlnhofer D., Klein C.A., Richter T., et al. Gene expression profiling of human stent induced neointima by cDNA array analysis of microscopic specimens retrieved by helix cutter atherectomy: detection of FK506-binding protein 12 upregulation. Circulation. 103:2001;1396-1402